Acute changes in sexual function, hormonal profiles, and psychological status following intensity-modulated radiotherapy in male patients with nasopharyngeal carcinoma - Summary - MDSpire
Advertisement
Acute changes in sexual function, hormonal profiles, and psychological status following intensity-modulated radiotherapy in male patients with nasopharyngeal carcinoma
To evaluate the acute effects of intensity-modulated radiotherapy (IMRT) on sexual function, sex hormone levels, and psychological status in male patients with nasopharyngeal carcinoma, and to assess the associations between changes in sexual function and hormonal and psychological parameters.
Key Findings:
Significant decrease in IIEF-5 and CIPE scores post-IMRT (p < 0.001).
Increased levels of FSH and PRL, and decreased levels of T and P post-treatment (all p < 0.001).
No significant changes in LH or E2 levels post-treatment.
Weak associations between sexual function scores and sex hormone levels (|r| < 0.2).
No significant changes in SAS and SDS scores post-IMRT.
Interpretation:
IMRT is associated with a significant decline in sexual function and alterations in sex hormone profiles in male patients with nasopharyngeal carcinoma, highlighting the need for clinical attention to these issues.
Limitations:
Retrospective design may introduce bias and limit causal inferences.
Small sample size may limit generalizability.
Short follow-up period does not assess long-term effects.
Conclusion:
Changes in sexual function showed weak associations with hormonal and psychological factors, indicating a need for further research and clinical strategies to address these issues.
High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.
